These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36966454)

  • 1. The therapeutic potential of immunotherapy in the treatment of breast cancer: Rational strategies and recent progress.
    Javid H; Attarian F; Saadatmand T; Rezagholinejad N; Mehri A; Amiri H; Karimi-Shahri M
    J Cell Biochem; 2023 Apr; 124(4):477-494. PubMed ID: 36966454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in Breast Cancer: When, How, and What Challenges?
    Henriques B; Mendes F; Martins D
    Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence.
    Abbaspour M; Akbari V
    Expert Rev Vaccines; 2022 Mar; 21(3):337-353. PubMed ID: 34932427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer vaccination: Latest advances with an analytical focus on clinical trials.
    Vajari MK; Sanaei MJ; Salari S; Rezvani A; Ravari MS; Bashash D
    Int Immunopharmacol; 2023 Oct; 123():110696. PubMed ID: 37494841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tremendous clinical potential of the microbiota in the treatment of breast cancer: the next frontier.
    Wu Y; Zhang Y; Zhang W; Huang Y; Lu X; Shang L; Zhou Z; Chen X; Li S; Cheng S; Song Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12513-12534. PubMed ID: 37382675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options.
    Singh K; Yadav D; Jain M; Singh PK; Jin JO
    Endocr Metab Immune Disord Drug Targets; 2022; 22(2):212-224. PubMed ID: 33902424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Molecular Combination Therapies Used for the Treatment of Breast Cancer.
    Wang Y; Minden A
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer under age 40: a different approach.
    Ribnikar D; Ribeiro JM; Pinto D; Sousa B; Pinto AC; Gomes E; Moser EC; Cardoso MJ; Cardoso F
    Curr Treat Options Oncol; 2015 Apr; 16(4):16. PubMed ID: 25796377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Breast Cancer: An Overlook on Current Strategies.
    Iacopetta D; Ceramella J; Baldino N; Sinicropi MS; Catalano A
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for the treatment of breast cancer.
    Moreno Ayala MA; Gottardo MF; Asad AS; Zuccato C; Nicola A; Seilicovich A; Candolfi M
    Expert Opin Biol Ther; 2017 Jul; 17(7):797-812. PubMed ID: 28446053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.
    Krasniqi E; Barchiesi G; Pizzuti L; Mazzotta M; Venuti A; Maugeri-Saccà M; Sanguineti G; Massimiani G; Sergi D; Carpano S; Marchetti P; Tomao S; Gamucci T; De Maria R; Tomao F; Natoli C; Tinari N; Ciliberto G; Barba M; Vici P
    J Hematol Oncol; 2019 Oct; 12(1):111. PubMed ID: 31665051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An efficient or methodical review of immunotherapy against breast cancer.
    Guanghui R; Xiaoyan H; Shuyi Y; Jun C; Guobin Q
    J Biochem Mol Toxicol; 2019 Aug; 33(8):e22339. PubMed ID: 31157481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Breast Cancer Treatment.
    Simonian M; Haji Ghaffari M; Negahdari B
    Iran Biomed J; 2021 Mar; 25(3):140-56. PubMed ID: 33724757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapeutic options for patients with refractory breast cancer.
    Fedele P; Ciccarese M; Surico G; Cinieri S
    Expert Opin Pharmacother; 2019 May; 20(7):851-861. PubMed ID: 30730767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How we treat HR-positive, HER2-negative early breast cancer.
    Lopez-Tarruella S; Echavarria I; Jerez Y; Herrero B; Gamez S; Martin M
    Future Oncol; 2022 Mar; 18(8):1003-1022. PubMed ID: 35094535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTLA-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer.
    Ghahremani Dehbokri S; Alizadeh N; Isazadeh A; Baghbanzadeh A; Abbaspour-Ravasjani S; Hajiasgharzadeh K; Baradaran B
    Curr Mol Med; 2023; 23(6):521-526. PubMed ID: 35692146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview.
    Crucitta S; Cucchiara F; Sciandra F; Cerbioni A; Diodati L; Rafaniello C; Capuano A; Fontana A; Fogli S; Danesi R; Re MD
    Anticancer Agents Med Chem; 2022; 22(4):760-774. PubMed ID: 34348634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.